Not all patients with psychotic disorders require a lifetime of antipsychotic treatment. A study of patients on the schizophrenia spectrum found that after a mean duration of illness of 10.4 years, 24 of 70 (34%) were free of antipsychotic medication for at least 3 months, of whom 20 were medicationfree for longer than a year.
1 Another study of first-episode psychosis reported that at 7-year follow-up, 17 of 103 patients (16.5%) had stopped antipsychotic medication during the previous 2 years. 2 Identifying clinical features of illness associated with lesser or greater likelihood of successfully discontinuing antipsychotic medication is of considerable importance. We report the proportion and factors associated with successful discontinuation during long-term follow-up of patients with first-episode psychosis.
Methods | We carried out a 10-year follow-up study of 178 patients with first-episode psychosis from a 1-year randomized clinical trial (RCT) of medication maintenance vs discontinuation to prevent relapse after complete resolution of initial psychotic symptoms in Hong Kong (NCT00334035). 3 After the RCT, all patients received usual psychiatric care, including medication at the discretion of patients and treating psychiatrists. Clinical outcomes were examined at 10 years in the patients who provided written informed consent (NCT01926340).
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Baseline measures (Table 1) were assessed using standardized assessments. Patients who had successfully discontinued medication were defined as having not received any antipsychotic drugs during the final 2 years of follow-up and being free of key positive symptoms of psychosis (Positive and Negative Syndrome Scale scores: delusions ≤2, conceptual disorganization ≤3, hallucinations ≤2, suspiciousness ≤4, and unusual thought content ≤3) 3 during the final month as assessed in a direct interview. Relapse during the follow-up period was assessed monthly through medical record review of a clinical global impression (CGI) of positive symptom severity. A relapse was defined as a change from a CGI positive score of less than 3 for at least 3 consecutive months to a score of 3 or more. (Apart from weekly consensus meetings between a clinician and raters, a CGI of positive symptoms was rated by the 3 raters from 8 independent medical records to ensure reliability; the intraclass correlation was 0.70, indicating good agreement.) Binary logistic regression analysis was used to identify potential associated factors in this study (age, sex, education, duration of untreated psychosis, premorbid function- Abbreviations: IQR, interquartile range; RCT, randomized clinical trial. a Premorbid adjustment scale was used to assess patients' premorbid functioning, including isolation, peer relations, scholastic performance, adaptation to school, and interests during childhood and adolescence using a 7-point scale, with 1 indicating the patient was very well adjusted and 7 indicating poor adjustment. b A lifetime diagnosis was made by a research psychiatrist using all available information over the full longitudinal course of illness, including a structured clinical interview for DSM-IV. c This score ranges from 1 to 100; a higher score indicates poorer functioning.
The score in the first 2 years after the start of the trial was averaged as a mean score of performance. Table 2) . Multivariate regression analysis showed that being relapse-free from baseline was the only statistically significant factor (odds ratio, 8.65 [95% CI, 2.65-28.27]; P < .001). The model explained 35.3% of the variance. Discussion | After 10 years, 16% of patients with first-episode psychosis (with complete initial response to treatment) could successfully stop medication in the final 2 years of follow-up and remain free of positive symptoms of psychosis. We note that this definition of successful discontinuation applies only to the final 2 years and the symptom remission criterion only to the final month. However, in Hong Kong, the presence of mild but definite delusions or hallucinations (Positive and Negative Syndrome Scale delusion and hallucinations scores equal to 3 5 )
would likely be an indication for restarting antipsychotic medication, so it is reasonable to posit that this group was relatively free of psychosis for much if not all of the preceding 2 years. Interestingly, using a different definition of successful discontinuation, a study in the Netherlands reported a similar rate (16%). 2 Being relapse-free, being male, having a shorter duration of untreated psychosis and a diagnosis other than one on the schizophrenia spectrum, having better functioning in the early phase of treatment, and remaining relapsefree in the placebo group during the RCT were individual factors associated with successful discontinuation, consistent with previous studies.
1,2
Diagnoses were longitudinal. Making an earlier, accurate diagnosis is challenging, and the present findings do not provide a test of the value of an accurate initial diagnosis in individual patients. Despite the small effect size, meta-analysis indicates an increased Stroop interference effect in schizophrenia. 6 The present findings suggest early evaluation of this measure could contribute to assessment of prognosis. Remaining relapse-free was the central most important predictor of successful long-term discontinuation, supporting interventions to prevent relapse. Table 1 .
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